
Capricor Therapeutics rose 45.9% from $5.69 to $8.30, ahead of the S&P 500's +11.2%. Its worst day was Jul 27 (−64.5%), and its low came Jul 31 at $3.85.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Capricor Therapeutics shares rose 460.0%, while the S&P 500 rose 0.1%.
+460.0%, the year's best day · S&P 500 +0.1%
EPS of $-0.62 missed the $-0.53 estimate on $0.00 revenue (est. $1.7M).
Story events cover the past 12 months · Times ET
−8.7% · S&P 500 −0.6%
Capricor Therapeutics closed at its highest level of the year, 521.1% above where the year started.
+3.3% · S&P 500 −0.7%
EPS of $-0.59 missed the $-0.54 estimate on $0.00 revenue (est. $25.2M).
−3.8% · S&P 500 +0.6%
Capricor Therapeutics closed at its lowest level of the year, 32.3% below where the year started.
−8.1% · S&P 500 +0.7%
EPS of $-0.70 missed the $-0.58 estimate on $0.00 revenue.
+58.0%, on 66M shares, the year's heaviest volume · S&P 500 −0.2%
EPS of $-0.73 missed the $-0.45 estimate on $0.00 revenue (est. $10.4M).
+26.5% · S&P 500 +1.3%
Where it ended: a close of $8.30 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.41, revenue est. $16.4M).
Nothing in the past 12 months.
All CAPR dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CAPR and SPY from Benzinga historical bars. Not investment advice.